ArticleEuropean journal of cell biology2017
EP4 receptor promotes invadopodia and invasion in human breast cancer.
Article in European journal of cell biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- The invadosome of stem-like cancer cells: metastasis machinery and targetable vulnerability.Cancer metastasis reviews · 2025Review
- Acquired resistance to jadomycin B in human triple-negative breast cancer cells is associated with increased cyclooxygenase-2 expression.The Journal of pharmacology and experimental therapeutics · 2025Article
- A phase I dose-escalation and expansion study of RMX1002, a selective E-type prostanoid receptor 4 antagonist, as monotherapy and in combination with anti-PD-1 antibody in advanced solid tumors.Investigational new drugs · 2025Article
- Molecular and Cellular Machinery of Lymphatic Metastasis in Breast Cancer.OncoTargets and therapy · 2025Review
- Remodeling the immune microenvironment for gastric cancer therapy through antagonism of prostaglandin E2 receptor 4.Genes & diseases · 2024Article
- Photodynamic Priming Improves the Anti-Migratory Activity of Prostaglandin E Receptor 4 Antagonist in Cancer Cells In Vitro.Cancers · 2021Article
- Time-Resolved Fluorescence Imaging and Analysis of Cancer Cell Invasion in the 3D Spheroid Model.Journal of visualized experiments : JoVE · 2021Article
- A Novel Invadopodia-Specific Marker for Invasive and Pro-Metastatic Cancer Stem Cells.Frontiers in oncology · 2021Article
- The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting.Frontiers in oncology · 2021Review
- Tissue remodeling by invadosomes.Faculty reviews · 2021Review
- Hold on or Cut? Integrin- and MMP-Mediated Cell-Matrix Interactions in the Tumor Microenvironment.International journal of molecular sciences · 2020Review
- Eicosanoids in Cancer: Prostaglandin EFrontiers in pharmacology · 2020Review
- Desmoglein 1 Regulates Invadopodia by Suppressing EGFR/Erk Signaling in an Erbin-Dependent Manner.Molecular cancer research : MCR · 2019Article
- miR-182 suppresses invadopodia formation and metastasis in non-small cell lung cancer by targeting cortactin gene.Journal of experimental & clinical cancer research : CR · 2018Article
- Discovery of an Experimental Model of Unicuspid Aortic Valve.Journal of the American Heart Association · 2018Article
- EP4 as a Therapeutic Target for Aggressive Human Breast Cancer.International journal of molecular sciences · 2018Review
- ECM Cross-Linking Regulates Invadopodia Dynamics.Biophysical journal · 2018Article
- Article
- Platelet "first responders" in wound response, cancer, and metastasis.Cancer metastasis reviews · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
Abstract
The production of Prostaglandin E
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.